Table 1 Cytotoxicity of compound 31 at five dose concentration level (0.01–100 µM).

Leukemia

CCRF-CEM

1.69

6.08

>1.00

HL-60(TB)

1.84

4.57

>1.00

K-562

2.57

>1.00

>1.00

MOLT-4

1.64

5.22

>1.00

RPMI-8226

0.80

3.99

>1.00

SR

2.87

>1.00

>1.00

Non-Small

Cell Lung

Cancer

A549/ATCC

1.94

3.54

6.46

EXVX

1.97

NT

>1.00

HOP-62

2.00

3.72

6.90

HOP-92

1.54

3.22

6.73

NCI-H226

1.69

3.79

NT

NCI-H23

2.01

4.09

NT

NCI-H322M

1.91

4.14

NT

NCI-H460

1.98

4.02

8.16

NCI-522

1.74

3.40

NT

Colon

Cancer

COLO 205

1.93

3.79

7.44

HCC-2998

1.81

3.46

659

HCT-116

1.70

NT

NT

HCT-15

2.07

NT

>1.00

HT29

2.44

5.20

>1.00

KM12

2.01

3.83

NT

SW-620

2.08

3.97

NT

CNS

Cancer

SF-268

1.59

3.15

6.23

SF-295

1.71

3.15

5.80

SF-539

1.63

3.15

6.10

SNB-19

2.11

4.95

>1.00

SNB-75

1.39

3.07

6.77

U251

1.91

3.65

6.98

Melanoma

LOX IMVI

1.68

3.22

NT

MALME-3M

2.11

3.75

6.68

M14

1.77

3.65

NT

MDA-MB-435

1.77

3.55

7.11

SK-MEL-2

1.74

3.35

6.45

SK-MEL-28

1.81

3.41

6.43

SK-MEL-5

1.49

2.83

5.39

UACC-257

2.10

3.62

6.24

UACC-62

1.70

3.36

NT

Ovarian

Cancer

IGROV1

2.04

NT

NT

OVCAR-3

1.83

3.36

6.20

OVCAR-4

2.17

6.30

>1.00

OVCAR-5

2.43

NT

>1.00

OVCAR-8

2.55

9.49

>1.00

NCI/ADR-RES

2.34

7.33

>1.00

SK-OV-3

2.27

4.10

7.42

Renal

Cancer

786-0

1.73

3.47

NT

A498

1.77

3.22

5.85

ACHN

1.68

3.07

5.61

CAKI-1

1.46

2.95

5.97

RXF 393

1.51

2.99

5.94

SN12C

2.05

4.53

>1.00

TK-10

2.02

3.65

NT

UO-31

1.49

2.85

5.46

Prostate

Cancer

PC-3

1.70

3.93

NT

DU-145

1.77

3.28

NT

Breast

Cancer

MCF7

1.80

4.58

>1.00

MDA-MB-231/ATCC

1.29

3.08

7.33

HS 578 T

2.39

6.74

>1.00

BT-549

1.94

3.64

6.82

T-47D

1.90

4.69

>1.00

MDA-MB-468

2.32

NT

>1.00

2.12

4.73

6.63